SPRUCE BIOSCIENCES INC SPRB

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 2.9m as of 2026-08-10, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $54.00.

Trends to Q2 2026

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

Fell to 5% or below in the last year: ORBIMED ADVISORS LLC (4.8%, 2026-08-14), ADAR1 Capital Management, LLC (2.5%, 2026-08-14), CITADEL ADVISORS LLC (1.9%, 2026-08-14), INTEGRATED CORE STRATEGIES (US) LLC (5.8%, 2026-08-04), WELLINGTON MANAGEMENT GROUP LLP (3.6%, 2026-05-15), Alyeska Investment Group, L.P. (4.5%, 2026-05-15), Squadron Capital Management LLC (0.9%, 2026-05-15), Ikarian Capital, LLC (4.8%, 2026-05-07), ExodusPoint Capital Management, LP (0.8%, 2026-04-28), Carlyle Group Inc. (4.7%, 2026-02-18)

Insider purchases and sales since 1 Apr 2026

Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.

None reported since 1 Apr 2026.

Holders, Q2 2026